Cellebrite DI (CLBT) Liabilities and Shareholders Equity (2020 - 2025)

Cellebrite DI's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $938.9 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 35.95% year-over-year to $938.9 million in Q4 2025; TTM through Dec 2025 was $3.3 billion, a 35.96% increase from a year earlier, with the FY2025 full-year figure at $938.9 million, up 35.95% from the prior year.
• Liabilities and Shareholders Equity advanced to $938.9 million in Q4 2025 per CLBT's latest filing, from $834.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $938.9 million in Q4 2025 and bottomed at $315.1 million in Q3 2021.
• The 5-year median for Liabilities and Shareholders Equity is $503.0 million (2023), against an average of $532.5 million.
• Across the five-year window, Liabilities and Shareholders Equity fell 6.75% in 2021 and surged 41.47% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $339.8 million in 2021, then climbed by 18.69% to $403.3 million in 2022, then soared by 32.13% to $532.9 million in 2023, then climbed by 29.59% to $690.6 million in 2024, then jumped by 35.95% to $938.9 million in 2025.
• Per Business Quant, the three latest CLBT Liabilities and Shareholders Equity figures stand at $938.9 million (Q4 2025), $834.3 million (Q3 2025), and $787.4 million (Q2 2025).